Common Questions and Answers about Multiple sclerosis journal treatments
multiple-sclerosis
i had been diagonised with multiplesclerosis in the year 2001. now i am not able to walk. i am also not able to see clearly. my speech is also not clear. i think my type of ms is primary progressive since my condition has worsened gradually. pl suggest some medicines or other alternative therapy.
The severity of chronic cerebrospinal venous insufficiency in patients with multiplesclerosis is related to altered cerebrospinal fluid dynamics.
Chronic cerebrospinal venous insufficiency (CCSVI) is a vascular picture that shows a strong association with multiple sclerosis (MS).
August 17, 2011
Chapter 4
Small-Molecule Treatments In Development for Multiple Sclerosis
Chapter 5
Monoclonal Antibodies in Development for Multiple Sclerosis
Chapter 6
Managing Symptoms in Multiple Sclerosis
Chapter 7
Prognostic Factors in Multiple Sclerosis
Chapter 8
Improving Immunosuppression and Immunomodulation Treatment Strategies in Multiple Sclerosis
Chapter 9
Neuroprotection and Neuroregeneration in MS
Chapter 10
Complementary and Alternative Medicine in Multiple Sclerosis
you mi
We'll soon be launching a Multiple Sclerosis Tracker, which will allow members to track symptoms and treatments related to Multiple Sclerosis. Please leave us a comment if you're interested in this tracker and we'll notify you when it's available.
Please join us for this unique opportunity to speak with our MS doctors about the advances that have been made in multiplesclerosis research and patient care. Thanks to your generous support, we are even closer to finding a cure for this debilitating disease.
Conclusions
Positive status with respect to anti–JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizumab treatment, alone or in combination, were associated with distinct levels of PML risk in natalizumab-treated patients with multiplesclerosis. (Funded by Biogen Idec and Elan Pharmaceuticals.)
http://www.nejm.org/doi/full/10.1056/NEJMoa1107829?
↓ Full text
MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiplesclerosis.↓ Full text
MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
One of the rare but not unheard of symptoms of multiple sclerosis (MS) is pruritis (itching), which can be included in the category of sensory abnormalities known as "dysesthesias." Because this type of itching is neurologically based, it does not respond to topical treatments like those used in allergic reactions. Anti-epileptic medications (gabapentin, carbamazepine, and phenytoin) are sometimes helpful in treating this problem."
this is from sharecare .
f only 12 brains and further work needs to be done to validate the studies findings. However, if this work reflects what is actually happening in multiplesclerosis, then its implications are earth shattering: Multiple sclerosis will no longer be an autoimmune disease. A lot of text books are going to have to be rewritten. Treatments that target inflammation will not not addressing the root cause of the diease.
my sister (24) was diagnosed MultipleSclerosis in 2010, responded to steroid. now she suffered sudden & complete loss of vision in her left eye. she has been put on SOLUMEDROL.
please suggest any available treatment modalities world over ? chances of return of vision ??
i had been diagonised with 
Recommended
